Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
IBJ-Iranian Biomedical Journal. 2018; 22 (1): 70-75
in English | IMEMR | ID: emr-190550

ABSTRACT

Background: Insulin-degrading enzyme [IDE] is a conserved zinc metallopeptidase. Here, we have evaluated the effect of passage number and culture time on IDE expression and activity in colorectal adenocarcinoma cell line [Caco-2]


Methods: Caco-2 cells were cultured with different passage ranges of 5-15, 25-35, 52-63 for 48, 72, and 120 hours. Subsequently, IDE expression and enzyme activity were assessed by Western blot analysis and fluorescent assay, respectively


Results: Our results confirmed that the amount of IDE was higher in cell extract compared to supernatant, and different passage numbers and culture times had small effect on IDE expression. However, when cells were cultured in the passage number range of 5-15 for 72 hours, the IDE activity was 35% higher compared to other passage numbers [p < 0.05]


Conclusion: The use of Caco-2 cells at passage number range of 5-15 and culture time of 72 hours provides proper conditions for IDE-related studies

2.
IJPR-Iranian Journal of Pharmaceutical Research. 2014; 13 (3): 819-833
in English | IMEMR | ID: emr-196696

ABSTRACT

In this study a 3-factor, 3-level Box-Behnken design was used to prepare optimized docetaxel [DTX] loaded pegylated poly lactide-co-glycolide [PEG-PLGA] NPs with polymer concentration [X1], drug concentration [X2] and ratio of the organic to aqueous solvent [X3] as the independent variables and particle size [Y1], poly dispersity index [PDI] [Y2] and drug loading [Y3] as the responses. The cytotoxicity of optimized DTX loaded PEG-PLGA NPs was studied in SKOV3 tumor cell lines by standard MTT assay. The in vivo antitumor efficacy of DTX loaded PLGA-PEG NPs was assessed in tumor bearing female BALB/c mice. The optimum level of Y1, Y2 and Y3 predicted by the model were 188 nm, 0.16 and 9% respectively with perfect agreement with the experimental data. The in vitro release profile of optimum formulation showed a burst release of approximately 20% [w/w] followed by a sustained release profile of the loaded drug over 288 h. The DTX loaded optimized nanoparticles showed a greater cytotoxicity against SKOV3 cancer cells than free DTX. Enhanced tumor-suppression effects were achieved with DTX-loaded PEG-PLGA NPs. These results demonstrated that optimized NPs could be a potentially useful delivery system for DTX as an anticancer agent

SELECTION OF CITATIONS
SEARCH DETAIL